Self Monitoring Blood Glucose (SMBG) Devices Market - Forecasts From 2018 to 2023
The global Self-Monitoring Blood Glucose (SMBG) Devices market is expected to reach US$13.412 billion by 2023 from US$10.125 billion in 2017 growing at a CAGR of 4.80%. Self-Blood Glucose Monitoring refers to the approach whereby people themselves their glycemic levels using a glycemic reader (glucose meter). Based on the glycemic levels, they can adjust or check the effect of their treatment (diet, exercise, insulin, antidiabetics and stress management) and also adjust the medication and diet as needed. These devices are easy to use and enable people to monitor their blood glucose level irrespective of the location and time. These devices are used for effective diabetes diagnosis and management. The Self-Monitoring Blood Glucose (SMBG) Devices market is expected to show robust growth during the forecast period owing to the rising prevalence of diabetes across the globe. Ease of use associated with the Self-Monitoring Blood Glucose (SMBG) Devices will also boost the market growth during the given forecast period. However, market growth of these devices may be hampered by lack of favourable reimbursement policies. Stringent regulatory environment will also retrain the growth of Self-Monitoring Blood Glucose (SMBG) devices during the given time-frame.
This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical region. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the global Healthcare Self-Monitoring Blood Glucose (SMBG) market value chain. Last step involves complete market engineering which includes analysing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the global Self-Monitoring Blood Glucose (SMBG) market.
Major industry players profiled as part of the report are Ascensia Diabetes Care Holdings AG, Sanofi and Ypsomed AG among others.
Segmentation
By Types
Blood Glucose Meters
Testing Strips
Lancets & Lancing Devices
By Indication
Type I Diabetes
Type II Diabetes
Gestational Diabetes
By End Users
Hospitals and Clinics
Ambulatory Care Settings
Diagnostic Centres
Home Care Settings
By Geography
North America
United States
Canada
Others
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
China
India
Australia
South Korea
Others
This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical region. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the global Healthcare Self-Monitoring Blood Glucose (SMBG) market value chain. Last step involves complete market engineering which includes analysing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the global Self-Monitoring Blood Glucose (SMBG) market.
Major industry players profiled as part of the report are Ascensia Diabetes Care Holdings AG, Sanofi and Ypsomed AG among others.
Segmentation
By Types
Blood Glucose Meters
Testing Strips
Lancets & Lancing Devices
By Indication
Type I Diabetes
Type II Diabetes
Gestational Diabetes
By End Users
Hospitals and Clinics
Ambulatory Care Settings
Diagnostic Centres
Home Care Settings
By Geography
North America
United States
Canada
Others
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
China
India
Australia
South Korea
Others
1. INTRODUCTION
1.1. Market Definition
1.2. Scope of the Study
1.3. Currency
1.4. Assumptions
1.5. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources
2.3. Validation
3. KEY FINDINGS OF THE STUDY
4. MARKET DYNAMICS
4.1. Drivers
4.2. Restraints
4.3. Opportunities and Market Trends
4.4. Market Segmentation
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Industry Value Chain Analysis
4.7. Industry Regulations
4.8. Scenario Analysis
5. SELF-MONITORING BLOOD GLUCOSE (SMBG) MARKET FORECAST BY TYPE
5.1. Blood Glucose Meters
5.2. Testing Strips
5.3. Lancets & Lancing Devices
6. SELF-MONITORING BLOOD GLUCOSE (SMBG) MARKET FORECAST BY INDICATION
6.1. Type I Diabetes
6.2. Type II Diabetes
6.3. Gestational Diabetes
7. SELF-MONITORING BLOOD GLUCOSE (SMBG) MARKET FORECAST BY END USERS
7.1. Hospitals and Clinics
7.2. Ambulatory Care Settings
7.3. Diagnostic Centres
7.4. Home Care Settings
8. SELF-MONITORING BLOOD GLUCOSE (SMBG) MARKET FORECAST BY GEOGRAPHY
8.1. North America
8.1.1. The U.S
8.1.2. Canada
8.1.3. Mexico
8.1.4. Others
8.2. South America
8.2.1. Brazil
8.2.2. Argentina
8.2.3. Others
8.3. Europe
8.3.1. U.K.
8.3.2. France
8.3.3. Germany
8.3.4. Italy
8.3.5. Others
8.4. Middle East and Africa
8.4.1. Saudi Arabia
8.4.2. UAE
8.4.3. Israel
8.4.4. Others
8.5. Asia Pacific
8.5.1. China
8.5.2. India
8.5.3. Australia
8.5.4. South Korea
8.5.5. Others
9. COMPETITIVE INTELLIGENCE
9.1. Market Share Analysis
9.2. Strategies of Key Players
9.3. Recent Investments and Deals
10. COMPANY PROFILES
10.1. Abbott
10.1.1. Overview
10.1.2. Financials
10.1.3. Product and Services
10.1.4. Recent Developments
10.2. Hoffmann-La Roche Ltd
10.2.1. Overview
10.2.2. Financials
10.2.3. Product and Services
10.2.4. Recent Developments
10.3. Lifescan Inc.
10.3.1. Overview
10.3.2. Financials
10.3.3. Product and Services
10.3.4. Recent Developments
10.4. Bayer Corporation
10.4.1. Overview
10.4.2. Financials
10.4.3. Product and Services
10.4.4. Recent Developments
10.5. ARKRAY, Inc.
10.5.1. Overview
10.5.2. Financials
10.5.3. Product and Services
10.5.4. Recent Developments
10.6. B. Braun Melsungen AG
10.6.1. Overview
10.6.2. Financials
10.6.3. Product and Services
10.6.4. Recent Developments
10.7. Sanofi
10.7.1. Overview
10.7.2. Financials
10.7.3. Product and Services
10.7.4. Recent Developments
10.8. Ypsomed AG
10.8.1. Overview
10.8.2. Financials
10.8.3. Product and Services
10.8.4. Recent Developments
10.9. Bionime Corporation
10.9.1. Overview
10.9.2. Financials
10.9.3. Product and Services
10.9.4. Recent Developments
10.10. Ascensia Diabetes Care Holdings AG
10.10.1. Overview
10.10.2. Financials
10.10.3. Product and Services
10.10.4. Recent Development
1.1. Market Definition
1.2. Scope of the Study
1.3. Currency
1.4. Assumptions
1.5. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources
2.3. Validation
3. KEY FINDINGS OF THE STUDY
4. MARKET DYNAMICS
4.1. Drivers
4.2. Restraints
4.3. Opportunities and Market Trends
4.4. Market Segmentation
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Industry Value Chain Analysis
4.7. Industry Regulations
4.8. Scenario Analysis
5. SELF-MONITORING BLOOD GLUCOSE (SMBG) MARKET FORECAST BY TYPE
5.1. Blood Glucose Meters
5.2. Testing Strips
5.3. Lancets & Lancing Devices
6. SELF-MONITORING BLOOD GLUCOSE (SMBG) MARKET FORECAST BY INDICATION
6.1. Type I Diabetes
6.2. Type II Diabetes
6.3. Gestational Diabetes
7. SELF-MONITORING BLOOD GLUCOSE (SMBG) MARKET FORECAST BY END USERS
7.1. Hospitals and Clinics
7.2. Ambulatory Care Settings
7.3. Diagnostic Centres
7.4. Home Care Settings
8. SELF-MONITORING BLOOD GLUCOSE (SMBG) MARKET FORECAST BY GEOGRAPHY
8.1. North America
8.1.1. The U.S
8.1.2. Canada
8.1.3. Mexico
8.1.4. Others
8.2. South America
8.2.1. Brazil
8.2.2. Argentina
8.2.3. Others
8.3. Europe
8.3.1. U.K.
8.3.2. France
8.3.3. Germany
8.3.4. Italy
8.3.5. Others
8.4. Middle East and Africa
8.4.1. Saudi Arabia
8.4.2. UAE
8.4.3. Israel
8.4.4. Others
8.5. Asia Pacific
8.5.1. China
8.5.2. India
8.5.3. Australia
8.5.4. South Korea
8.5.5. Others
9. COMPETITIVE INTELLIGENCE
9.1. Market Share Analysis
9.2. Strategies of Key Players
9.3. Recent Investments and Deals
10. COMPANY PROFILES
10.1. Abbott
10.1.1. Overview
10.1.2. Financials
10.1.3. Product and Services
10.1.4. Recent Developments
10.2. Hoffmann-La Roche Ltd
10.2.1. Overview
10.2.2. Financials
10.2.3. Product and Services
10.2.4. Recent Developments
10.3. Lifescan Inc.
10.3.1. Overview
10.3.2. Financials
10.3.3. Product and Services
10.3.4. Recent Developments
10.4. Bayer Corporation
10.4.1. Overview
10.4.2. Financials
10.4.3. Product and Services
10.4.4. Recent Developments
10.5. ARKRAY, Inc.
10.5.1. Overview
10.5.2. Financials
10.5.3. Product and Services
10.5.4. Recent Developments
10.6. B. Braun Melsungen AG
10.6.1. Overview
10.6.2. Financials
10.6.3. Product and Services
10.6.4. Recent Developments
10.7. Sanofi
10.7.1. Overview
10.7.2. Financials
10.7.3. Product and Services
10.7.4. Recent Developments
10.8. Ypsomed AG
10.8.1. Overview
10.8.2. Financials
10.8.3. Product and Services
10.8.4. Recent Developments
10.9. Bionime Corporation
10.9.1. Overview
10.9.2. Financials
10.9.3. Product and Services
10.9.4. Recent Developments
10.10. Ascensia Diabetes Care Holdings AG
10.10.1. Overview
10.10.2. Financials
10.10.3. Product and Services
10.10.4. Recent Development
